High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation.


Journal

Metabolic syndrome and related disorders
ISSN: 1557-8518
Titre abrégé: Metab Syndr Relat Disord
Pays: United States
ID NLM: 101150318

Informations de publication

Date de publication:
05 2020
Historique:
pubmed: 3 3 2020
medline: 8 6 2021
entrez: 3 3 2020
Statut: ppublish

Résumé

Current algorithms for assessing risk of atherosclerotic cardiovascular disease (ASCVD) and, in particular, the reliance on low-density lipoprotein (LDL) cholesterol in conditions where this measurement is discordant with apoB and LDL-particle concentrations fail to identify a sizeable part of the population at high risk for adverse cardiovascular events. This results in missed opportunities for ASCVD prevention, most notably in those with metabolic syndrome, prediabetes, and diabetes. There is substantial evidence that accumulation of ectopic fat and associated metabolic traits are markers for and pathogenic components of high-risk atherosclerosis. Conceptually, the subset of advanced lesions in high-risk atherosclerosis that triggers vascular complications is closely related to a set of coordinated high-risk traits clustering around a distinct metabolic phenotype. A key feature of this phenotype is accumulation of ectopic fat, which, coupled with age-related muscle loss, creates a milieu conducive for the development of ASCVD: atherogenic dyslipidemia, nonresolving inflammation, endothelial dysfunction, hyperinsulinemia, and impaired fibrinolysis. Sustained vascular inflammation, a hallmark of high-risk atherosclerosis, impairs plaque stabilization in this phenotype. This review describes how metabolic and inflammatory processes that are promoted in large measure by ectopic adiposity, as opposed to subcutaneous adipose tissue, relate to the pathogenesis of high-risk atherosclerosis. Clinical biomarkers indicative of these processes provide incremental information to standard risk factor algorithms and advanced lipid testing identifies atherogenic lipoprotein patterns that are below the discrimination level of standard lipid testing. This has the potential to enable improved identification of high-risk patients who are candidates for therapeutic interventions aimed at prevention of ASCVD.

Identifiants

pubmed: 32119801
doi: 10.1089/met.2019.0115
pmc: PMC7196362
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

176-185

Références

JAMA. 2009 Nov 11;302(18):1993-2000
pubmed: 19903920
JAMA Cardiol. 2019 Oct 23;:
pubmed: 31642874
J Am Coll Cardiol. 2019 Mar 5;73(8):948-963
pubmed: 30819364
Arch Intern Med. 2005 Jun 27;165(12):1395-400
pubmed: 15983289
Am J Cardiol. 2005 Aug 1;96(3):399-404
pubmed: 16054467
Circ Res. 2018 Sep 14;123(7):886-904
pubmed: 30355075
J Clin Lipidol. 2011 Sep-Oct;5(5):338-67
pubmed: 21981835
Am J Clin Nutr. 2017 Oct;106(4):984-995
pubmed: 28814394
Eur Heart J. 2014 Jul 14;35(27):1782-91
pubmed: 24864079
Eur Heart J. 2018 Oct 7;39(38):3499-3507
pubmed: 30165610
Science. 2018 Nov 16;362(6416):770-775
pubmed: 30442801
Clin Chem. 2017 Dec;63(12):1886-1896
pubmed: 29021325
Physiol Rev. 2018 Oct 1;98(4):2133-2223
pubmed: 30067154
Eur J Pharmacol. 2016 Aug 15;785:24-35
pubmed: 27085899
Nat Rev Immunol. 2019 Sep;19(9):563-572
pubmed: 31175337
Circulation. 2012 Sep 4;126(10):1301-13
pubmed: 22949540
Circ Res. 2019 May 10;124(10):1425-1427
pubmed: 31070997
Eur Heart J. 2018 Jul 14;39(27):2562-2573
pubmed: 29982602
Trends Endocrinol Metab. 2018 Oct;29(10):699-711
pubmed: 30145108
Mediators Inflamm. 2017;2017:3102737
pubmed: 29445255
BMJ. 2014 Jul 18;349:g4379
pubmed: 25038074
Nutrients. 2013 Mar 18;5(3):928-48
pubmed: 23507795
Nat Rev Cardiol. 2018 Sep;15(9):505-522
pubmed: 30065258
Neuroendocrinology. 2017;104(4):347-363
pubmed: 27846625
Clin Endocrinol (Oxf). 2009 Jun;70(6):870-5
pubmed: 18771560
Arterioscler Thromb Vasc Biol. 2014 May;34(5):959-61
pubmed: 24740188
Diabetologia. 2018 Feb;61(2):273-283
pubmed: 29143063
Eur Heart J. 2015 Mar 1;36(9):539-50
pubmed: 24474739
Lancet Diabetes Endocrinol. 2017 Oct;5(10):774-787
pubmed: 28864143
J Am Coll Cardiol. 2018 Jul 17;72(3):330-343
pubmed: 29935936
Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):553-9
pubmed: 15618542
J Am Heart Assoc. 2019 Nov 19;8(22):e012881
pubmed: 31711385
J Lipid Res. 2002 Sep;43(9):1363-79
pubmed: 12235168
Eur Heart J. 2018 Jul 14;39(27):2574-2576
pubmed: 29982362
Nat Med. 2015 Mar;21(3):263-9
pubmed: 25686106
Nat Rev Endocrinol. 2012 Apr 03;8(8):457-65
pubmed: 22473333
Cell Metab. 2020 Feb 4;31(2):233-249.e4
pubmed: 31866441
Aging Dis. 2018 Oct 1;9(5):880-900
pubmed: 30271665
BMJ. 2019 Jul 3;366:l4137
pubmed: 31270106
Cell Metab. 2018 Oct 2;28(4):547-556.e3
pubmed: 30078554
J Am Heart Assoc. 2016 Jun 21;5(6):
pubmed: 27329448
Arterioscler Thromb Vasc Biol. 2014 May;34(5):1069-77
pubmed: 24558110
Nat Rev Cardiol. 2019 Feb;16(2):83-99
pubmed: 30287946
JAMA. 2000 Jan 12;283(2):221-8
pubmed: 10634338
Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):196-201
pubmed: 24233487
Eur J Prev Cardiol. 2020 Mar;27(4):394-406
pubmed: 31408370
Circulation. 2007 Oct 16;116(16):1832-44
pubmed: 17938300
Nat Immunol. 2020 Jan;21(1):30-41
pubmed: 31819254
Diabetes Care. 2016 Nov;39(11):2080-2088
pubmed: 27926891
J Clin Lipidol. 2016 Sep-Oct;10(5):1248-58
pubmed: 27678443
Circulation. 2003 Jul 29;108(4):420-5
pubmed: 12860914
JAMA Cardiol. 2019 Jul 17;:
pubmed: 31314049
Visc Med. 2016 Oct;32(5):319-326
pubmed: 27921043
N Engl J Med. 2019 Dec 26;381(26):2541-2551
pubmed: 31881139
Eur Heart J. 2019 Sep 7;40(34):2849-2855
pubmed: 31256194
Circulation. 2000 Jul 11;102(2):179-84
pubmed: 10889128
JAMA Cardiol. 2019 Apr 1;4(4):321-329
pubmed: 30865212
Nat Rev Cardiol. 2018 Dec;15(12):731-743
pubmed: 30115967
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Atheroscler Suppl. 2002 Dec;3(4):57-68
pubmed: 12573364
JAMA Cardiol. 2019 Jul 17;:
pubmed: 31314043
Am J Clin Nutr. 2006 May;83(5):1025-31; quiz 1205
pubmed: 16685042
Medicine (Baltimore). 2018 Sep;97(37):e12271
pubmed: 30212963
Endocr Pract. 2003 Sep-Oct;9 Suppl 2:67-72
pubmed: 14698979
Circ Res. 2016 May 27;118(11):1808-29
pubmed: 27230643
J Am Heart Assoc. 2018 Apr 13;7(8):
pubmed: 29654193
J Am Coll Cardiol. 2018 May 22;71(20):2360-2372
pubmed: 29773163
Circulation. 2015 Dec 8;132(23):2220-9
pubmed: 26408274
N Engl J Med. 2019 Feb 21;380(8):752-762
pubmed: 30415610
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337457
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1754-9
pubmed: 22815340
Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):157-168
pubmed: 31641012
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Nat Rev Cardiol. 2019 Oct;16(10):581-601
pubmed: 31097791
Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):538-545
pubmed: 30816799
Nat Rev Cardiol. 2019 Jul;16(7):389-406
pubmed: 30846875
Diabetes Metab Res Rev. 2007 Jan;23(1):14-20
pubmed: 17080469
J Clin Invest. 2018 Jul 2;128(7):2713-2723
pubmed: 30108191
J Am Coll Cardiol. 2013 Nov 12;62(20):1826-33
pubmed: 23973693
J Nephrol. 1997 Jul-Aug;10(4):188-91
pubmed: 9377725
N Engl J Med. 2014 Dec 4;371(23):2237-8
pubmed: 25470706
Circulation. 2018 Mar 13;137(11):1143-1157
pubmed: 29142011
Am J Cardiol. 2016 Jun 15;117(12):1921-7
pubmed: 27156827
Circulation. 2019 Aug 13;140(7):553-555
pubmed: 31403842
J Clin Lipidol. 2019 Mar - Apr;13(2):326-334.e2
pubmed: 30665770
Circulation. 2019 Sep 17;140(12):e673-e691
pubmed: 31422671
Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1225-36
pubmed: 18565848

Auteurs

Katharina Lechner (K)

Department of Prevention, Rehabilitation and Sports Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.

Amy L McKenzie (AL)

Virta Health, San Francisco, California, USA.

Nicolle Kränkel (N)

Klinik Für Kardiologie, Campus Benjamin Steglitz, Charité-Universitätsmedizin Berlin, Berlin, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.

Clemens Von Schacky (C)

Preventive Cardiology, Ludwig-Maximilians University, Munich, Germany.
Omegametrix, Martinsried, Germany.

Nicolai Worm (N)

German University for Prevention and Health Care Management, Saarbrücken, Germany.

Uwe Nixdorff (U)

European Prevention Center, Düsseldorf, Germany.

Benjamin Lechner (B)

Department of Internal Medicine IV, Ludwig-Maximilians University, Munich, Germany.

Johannes Scherr (J)

Department of Prevention, Rehabilitation and Sports Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
University Center for Prevention and Sports Medicine, Balgrist University Hospital, University of Zurich, Zurich, Switzerland.

Oliver Weingärtner (O)

Klinik Für Innere Medizin I, Universitätsklinikum Jena, Jena, Germany.

Ronald M Krauss (RM)

University of California, San Francisco, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH